DK3398594T3 - Sammensætninger til forbedring af hjernefunktion - Google Patents
Sammensætninger til forbedring af hjernefunktion Download PDFInfo
- Publication number
- DK3398594T3 DK3398594T3 DK18178948.8T DK18178948T DK3398594T3 DK 3398594 T3 DK3398594 T3 DK 3398594T3 DK 18178948 T DK18178948 T DK 18178948T DK 3398594 T3 DK3398594 T3 DK 3398594T3
- Authority
- DK
- Denmark
- Prior art keywords
- compositions
- brain function
- improving brain
- improving
- function
- Prior art date
Links
- 230000003925 brain function Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01001—Alpha-amylase (3.2.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261703163P | 2012-09-19 | 2012-09-19 | |
| SE1200567 | 2012-09-19 | ||
| EP13773433.1A EP2897604B1 (en) | 2012-09-19 | 2013-09-19 | Compositions for improvement of brain function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3398594T3 true DK3398594T3 (da) | 2024-09-23 |
Family
ID=49304297
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18178948.8T DK3398594T3 (da) | 2012-09-19 | 2013-09-19 | Sammensætninger til forbedring af hjernefunktion |
| DK13773433.1T DK2897604T3 (da) | 2012-09-19 | 2013-09-19 | Sammensætninger til forbedring af hjernefunktion |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13773433.1T DK2897604T3 (da) | 2012-09-19 | 2013-09-19 | Sammensætninger til forbedring af hjernefunktion |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9592211B2 (da) |
| EP (2) | EP2897604B1 (da) |
| JP (2) | JP6263540B2 (da) |
| KR (1) | KR102198633B1 (da) |
| CN (1) | CN104797248B (da) |
| AU (1) | AU2013318686B2 (da) |
| CA (1) | CA2884592C (da) |
| DK (2) | DK3398594T3 (da) |
| ES (2) | ES2681343T3 (da) |
| FI (1) | FI3398594T3 (da) |
| HK (1) | HK1207566A1 (da) |
| PL (2) | PL2897604T3 (da) |
| WO (1) | WO2014046603A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104797248B (zh) * | 2012-09-19 | 2017-10-31 | 格雷斯珀公司 | 用于改善脑功能的组合物 |
| WO2016083399A1 (en) * | 2014-11-24 | 2016-06-02 | Forschungsgesellschaft Für Arbeitsphysiologie Und Arbeitsschutz E. V. | Alpha-ketoglutarate in combination with glutamate dehydrogenase for treating hyperammonemia |
| US20200253907A1 (en) * | 2017-08-21 | 2020-08-13 | The Regents Of The University Of California | Compositions and Methods for Treating Neurodegenerative Diseases |
| PE20211816A1 (es) | 2018-09-25 | 2021-09-14 | Ponce De Leon Health Designated Activity Company | Proceso de elaboracion de alfa-cetoglutarato de calcio |
| US20230310559A1 (en) * | 2020-08-18 | 2023-10-05 | St. Jude Children's Research Hospital, Inc. | Use of Amylase or Maltose to Treat or Prevent Neurodegeneration |
| WO2023200281A1 (ko) * | 2022-04-15 | 2023-10-19 | 재단법인대구경북과학기술원 | 알츠하이머병 또는 경도 인지장애 진단을 위한 비응집성 용해조성물 및 이를 이용한 진단 방법 |
| CN117530940A (zh) * | 2023-10-11 | 2024-02-09 | 四川大学华西第二医院 | α-酮戊二酸在制备促髓鞘修复、改善神经炎症的药物中的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2711436B2 (ja) | 1995-02-22 | 1998-02-10 | マルホ株式会社 | アレルギー治療剤及びアレルギー対応食品 |
| US6051220A (en) | 1995-05-31 | 2000-04-18 | Medzyme N.V. And Simon Lodewijk Scharpe | Composition to improve digestibility and utilization of nutrients |
| US6372473B1 (en) | 1997-05-28 | 2002-04-16 | Human Genome Sciences, Inc. | Tissue plasminogen activator-like protease |
| WO1999021565A1 (en) | 1997-10-24 | 1999-05-06 | Cornell Research Foundation, Inc. | Nutritional supplement for cerebral metabolic insufficiencies |
| US20010046493A1 (en) | 2000-02-24 | 2001-11-29 | Alex Margolin | Lipase-containing composition and methods of use thereof |
| US20070053895A1 (en) * | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
| PL198969B1 (pl) | 2001-01-09 | 2008-08-29 | Louis Johan Wagenaar | Zastosowanie dekspantenolu jako składnika kompozycji do pielęgnacji soczewek kontaktowych |
| AR032392A1 (es) | 2001-01-19 | 2003-11-05 | Solvay Pharm Gmbh | Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado. |
| US6689810B2 (en) | 2001-08-21 | 2004-02-10 | Cellular Sciences, Inc. | Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide |
| US8076373B2 (en) | 2001-09-11 | 2011-12-13 | North Cell Pharmacetical | Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite |
| US7122578B2 (en) | 2001-09-11 | 2006-10-17 | Alain Martin | Method and composition for treating mammalian diseases and injuries which cause pain, erythema, swelling, crusting, ischemia scarring and excess white blood cell infiltration |
| US7241456B2 (en) | 2002-10-25 | 2007-07-10 | Australian Importers Ltd. | Formulations for topical delivery of bioactive substances and methods for their use |
| JP4265997B2 (ja) | 2004-07-14 | 2009-05-20 | 富士通マイクロエレクトロニクス株式会社 | 半導体装置及びその製造方法 |
| PL369552A1 (pl) * | 2004-08-12 | 2006-02-20 | Sgp & Sons Ab | Preparat farmaceutyczny lub/i żywieniowy lub/i laboratoryjny wzmagający, wspomagający funkcjonowanie komórek nerwowych i układu nerwowego oraz zastosowanie preparatu farmaceutycznego lub/i żywieniowego w procesie ochrony funkcji układu nerwowego oraz zastosowanie preparatu do ochrony wzrostu stymulacji namnażania i zapobiegania apoptozie komórek nerwowych |
| PT2198880T (pt) | 2004-10-14 | 2017-01-04 | Lilly Co Eli | Composições contendo lipase, protease e amilase para o tratamento de insuficiência pancreática |
| CA2911468C (en) | 2004-12-17 | 2018-04-24 | Alan B. Cash | Oxaloacetate, oxaloacetic acid, and oxaloacetate salts for delaying the onset of neurodegenerative diseases |
| WO2007082914A2 (en) | 2006-01-19 | 2007-07-26 | Entress Ab | Method of diagnosis and method of treatment |
| PL226695B1 (pl) | 2006-07-03 | 2017-08-31 | Danuta Kruszewska | Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori |
| PT1915913E (pt) | 2006-10-23 | 2016-02-16 | Nestec Sa | Modulação do sabor e do aroma de produtos lácteos por biotransformação |
| NZ579047A (en) * | 2007-02-20 | 2012-03-30 | Aptalis Pharma Ltd | Stable digestive enzyme compositions |
| US11016104B2 (en) | 2008-07-01 | 2021-05-25 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
| US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
| EA201101519A1 (ru) | 2009-05-11 | 2012-10-30 | БЕРГ БАЙОСИСТЕМЗ, ЭлЭлСи | Способы диагностики метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния |
| CN101884631A (zh) | 2009-05-12 | 2010-11-17 | 复旦大学 | 基于α酮戊二酸及其衍生物的抗肿瘤药物 |
| CN102010890B (zh) * | 2009-09-08 | 2013-05-22 | 北京迪迈医学诊断技术有限公司 | 线粒体天门冬氨酸氨基转移酶测定试剂盒 |
| US20110064712A1 (en) * | 2009-09-16 | 2011-03-17 | Daniel Moses Amato | Dietary Supplement Compositions and Methods of Making and Using the Same |
| US9050306B2 (en) | 2010-06-22 | 2015-06-09 | Alan B. Cash | Activation of AMP-protein activated kinase by oxaloacetate compounds |
| CA2808978A1 (en) | 2010-08-23 | 2012-03-01 | Shmuel Ben-Sasson | Compositions for gastric delivery of active agents |
| WO2012078798A1 (en) | 2010-12-07 | 2012-06-14 | Bananalogix, Inc. | Methods of processing organic matter and compositions thereof |
| CN104797248B (zh) * | 2012-09-19 | 2017-10-31 | 格雷斯珀公司 | 用于改善脑功能的组合物 |
-
2013
- 2013-09-19 CN CN201380058821.4A patent/CN104797248B/zh active Active
- 2013-09-19 WO PCT/SE2013/051098 patent/WO2014046603A1/en active Application Filing
- 2013-09-19 JP JP2015533015A patent/JP6263540B2/ja active Active
- 2013-09-19 PL PL13773433T patent/PL2897604T3/pl unknown
- 2013-09-19 PL PL18178948.8T patent/PL3398594T3/pl unknown
- 2013-09-19 AU AU2013318686A patent/AU2013318686B2/en active Active
- 2013-09-19 KR KR1020157009161A patent/KR102198633B1/ko active Active
- 2013-09-19 ES ES13773433.1T patent/ES2681343T3/es active Active
- 2013-09-19 ES ES18178948T patent/ES2993163T3/es active Active
- 2013-09-19 EP EP13773433.1A patent/EP2897604B1/en active Active
- 2013-09-19 FI FIEP18178948.8T patent/FI3398594T3/sv active
- 2013-09-19 CA CA2884592A patent/CA2884592C/en active Active
- 2013-09-19 DK DK18178948.8T patent/DK3398594T3/da active
- 2013-09-19 EP EP18178948.8A patent/EP3398594B1/en active Active
- 2013-09-19 DK DK13773433.1T patent/DK2897604T3/da active
- 2013-09-19 US US14/428,841 patent/US9592211B2/en active Active
-
2015
- 2015-08-24 HK HK15108187.9A patent/HK1207566A1/xx unknown
-
2017
- 2017-03-02 US US15/447,974 patent/US20170333372A1/en not_active Abandoned
- 2017-10-25 JP JP2017205991A patent/JP2018048175A/ja active Pending
-
2021
- 2021-01-29 US US17/163,065 patent/US20210154160A1/en not_active Abandoned
-
2023
- 2023-10-25 US US18/494,126 patent/US20240065993A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3398594B1 (en) | 2024-07-10 |
| ES2993163T3 (en) | 2024-12-23 |
| PL2897604T3 (pl) | 2018-10-31 |
| KR102198633B1 (ko) | 2021-01-05 |
| JP2015529245A (ja) | 2015-10-05 |
| EP2897604A1 (en) | 2015-07-29 |
| AU2013318686A1 (en) | 2015-04-02 |
| US9592211B2 (en) | 2017-03-14 |
| US20210154160A1 (en) | 2021-05-27 |
| AU2013318686B2 (en) | 2017-11-30 |
| CN104797248B (zh) | 2017-10-31 |
| CN104797248A (zh) | 2015-07-22 |
| WO2014046603A1 (en) | 2014-03-27 |
| JP2018048175A (ja) | 2018-03-29 |
| FI3398594T3 (en) | 2024-09-23 |
| EP2897604B1 (en) | 2018-07-04 |
| PL3398594T3 (pl) | 2024-11-04 |
| JP6263540B2 (ja) | 2018-01-17 |
| DK2897604T3 (da) | 2018-08-06 |
| US20240065993A1 (en) | 2024-02-29 |
| US20150297544A1 (en) | 2015-10-22 |
| ES2681343T3 (es) | 2018-09-12 |
| KR20150058292A (ko) | 2015-05-28 |
| CA2884592A1 (en) | 2014-03-27 |
| US20170333372A1 (en) | 2017-11-23 |
| EP3398594A1 (en) | 2018-11-07 |
| CA2884592C (en) | 2021-08-31 |
| HK1207566A1 (en) | 2016-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3225604T3 (da) | Fremgangsmåde til fremstilling af flerlagsruder | |
| CO7010838A2 (es) | Compuestos de imidazopirrolidinona | |
| DK3725778T3 (da) | Formuleringer af enzalutamid | |
| PT3068786T (pt) | Compostos de pirazolopirimidina | |
| DK2906696T3 (da) | Fremgangsmåder til modulering af c9orf72-ekspression | |
| BR112013017183A2 (pt) | composições de bepostatina | |
| DK2911506T3 (da) | Driftreducerende sammensætninger | |
| BR112014032798A2 (pt) | composição | |
| CO6990736A2 (es) | Pirrolidina-2-carboxamidas sustituídas | |
| DK2708147T3 (da) | Fremgangsmåder til forøgelse af hjernefunktionalitet under anvendelse af 2-fucosyl-lactose | |
| BR112014019470A2 (pt) | conjunto de disjuntor | |
| EP2900621A4 (en) | BIOKERAMIKZUSAMMENSETZUNGEN | |
| BR112015003038A2 (pt) | composições lubrificantes | |
| EP2934454C0 (en) | ANTI-DANDRUFF COMPOSITION | |
| ME03413B (me) | Kompozicije које sadrže peg i askorbat | |
| EP2807289A4 (en) | ETCHING COMPOSITION | |
| DK2822967T3 (da) | Compositions comprising secretory - like immunoglobulins | |
| DK2804611T3 (da) | Chitosanafledte forbindelser | |
| FR2993777B1 (fr) | Composition photo-protectrice | |
| EP2832832A4 (en) | LUBRICATING OIL COMPOSITION | |
| DK3398594T3 (da) | Sammensætninger til forbedring af hjernefunktion | |
| EP2920370A4 (en) | POST | |
| DK2916661T3 (da) | Fremgangsmåde til opnåelse af bloom-hæmmende komponenter til konfektureprodukter | |
| DK2809782T3 (da) | Forbedret fremgangsmåde til fremstilling af makrokugler | |
| DK2872536T3 (da) | Fremgangsmåde til ekstraktion af biomasse |